At present, there are no efficient methods to obtain pure melanin in significant quantities. Melanin is isolated from skin or hair biopsies, but in a very small amount in a highly degraded condition. The in vitro cell culture protocol we have developed is a very efficient system that allows obtaining large amounts of melanin in non-degraded form.

Obtained from the cells we cultured, melanin can find many potential industrial applications, including in cosmetology or preventive oncology, as a substrate for the development of a new generation of natural creams that protect against UV radiation and thus against the development of skin cancers. Obtained pigmented cells may also find application in the treatment of vitiligo patients as they can be a natural substitute for melanocytes that play a key role in pigmentation disorders.

The dermatological preparations / cosmetics market is one of the most dynamically growing markets. According to various reports, the value of the dermopreparation market by 2015 was to increase to over USD 63 billion in Europe and USD 58 billion in the USA. In Germany, one of the most important markets in Europe, sales increase by about 7% annually. The French market is growing the most dynamically on our continent, recording a 14% increase in sales.

Currently, our technology is at the TLR5 level. The complete protocol for differentiating cells into pigmented cells has been verified in laboratory conditions. The resulting pigment was identified as melanin by means of electron paramagnetic resonance (EPR). In turn, the obtained pigmented cells were characterized by transmission electron microscopy (TEM) and immunocytochemical staining (ICC), as well as for gene expression analysis by PCR. The scale of the process is currently at semi-industrial / industrial level.

We are looking for business partner that will enable us to prepare the product prototype and launch the production line.

Marcin Majka
Jagiellonian university

Prof. Majka has long lasting interest in basic and clinical stem cells research. He has received his PhD from Pomeranian School of Medicine in stem cells biology field. He has spent his postdoctoral fellowship at the University of Pennsylvania and University of Louisville, USA. He came back to Poland in 2003 and since than he has participated in several clinical trials including one of the largest trials on the use of bone marrow stem cells in the treatment of myocardial infarction – REGENT. His recent achievements in the clinic stem cells research field include pioneering publication on the use of bone marrow cells for the treatment of spinal cord injury and drug resistant epilepsy in pediatric patients. He was also involved in clinical trials on the use of mesenchymal stem cells in Graft versus Host Diseases after allogeneic HSC transplantation; use of myoblast in Stress Urinary Incontinence treatment; use of mesenchymal stem cells in Osteogenesis Imperfecta. Recently, research conducted by prof. Majka also includes induce pluripotent stem cells and genome editing. Prof. Majka research also involves projects related to progression and metastasis of pediatric tumors.